SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Charlotte Brontë Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientCharlotte Brontë
Date of birth1816-04-21
IdentifiersMRN HR-NI025-SYN-TD; SSN (made up) 000-25-3804
Document date2026-11-01
AuthorEleanor Thwaite, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

First prenatal visit at 7 weeks with nausea and vomiting for a week and early weight loss: dating ultrasound, prenatal tests, and a plan for the nausea. Concerns: Nausea most of the day for a week and vomiting three or four times a day; she can no longer face meals and has lost about a kilogram; She is glad of the pregnancy but anxious about her age and about her own health, having lost her mother and her sisters young; She asks whether she could carry tuberculosis, since it was in her household. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe)One tablet by mouth dailyOral route1855-01-13activeS
Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, two tablets by mouth at bedtimeTwo tablets by mouth at bedtimeOral route1855-01-13 to 1855-01-20completedS
Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day)One tablet in the morning, one mid-afternoon, and two at bedtimeOral route1855-01-20activeS
Metoclopramide 10 mg oral tablet, one tablet by mouth three times a day before mealsOne tablet by mouth three times a day, 30 minutes before mealsOral route1855-01-20 to 1855-01-29completedS
Sodium chloride 0.9% with potassium chloride 20 mmol per liter, 1000 mL intravenously over 8 hours1000 mL over 8 hours, guided by daily electrolytesIntravenous route1855-01-29 to 1855-02-01completedS
Thiamine 100 mg intravenously daily, the first dose before any dextrose100 mg intravenously once daily; first dose before any dextrose-containing fluidIntravenous route1855-01-29 to 1855-02-01completedS
Ondansetron 4 mg intravenously every 8 hours4 mg by slow intravenous injection every 8 hoursIntravenous route1855-01-29 to 1855-02-01completedS
Enoxaparin 20 mg subcutaneously once daily during the admission (weight under 50 kg)20 mg (0.2 mL) subcutaneously once daily while in hospitalSubcutaneous route1855-01-29 to 1855-02-01completedS
Magnesium sulfate 2 g in 50 mL intravenously over 1 hour, once2 g intravenously over 1 hour, one doseIntravenous route1855-01-29 to 1855-01-29completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hoursOne tablet on the tongue every 8 hoursOral route1855-02-01 to 1855-02-24completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nauseaOne tablet on the tongue up to every 8 hours if neededOral route1855-02-24 to 1855-03-24completedS
Thiamine 100 mg oral tablet, one tablet by mouth three times a dayOne tablet by mouth three times a day while intake is poorOral route1855-02-01 to 1855-02-24completedS
Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtimeOne tablet by mouth at bedtime until deliveryOral route1855-02-24activeS

Procedures

ProcedureDatesStatusEvidence
Transvaginal dating ultrasound: single live intrauterine pregnancy, crown-rump length 11 mm (7 weeks 1 day), cardiac activity present, no subchorionic hemorrhage, ovaries normal1855-01-13 to 1855-01-13completedS
12-lead electrocardiogram before intravenous ondansetron with hypokalemia: sinus tachycardia 106 per minute, QTc 438 ms, no other abnormality1855-01-29 to 1855-01-29completedS
First-trimester ultrasound for nuchal translucency: single live fetus, crown-rump length 70 mm (13 weeks 1 day), nuchal translucency 1.5 mm, nasal bone present, no structural abnormality seen1855-02-24 to 1855-02-24completedS

Immunizations

DateVaccineStatusEvidence
1855-01-13Influenza vaccine, 1854-1855 season, given in pregnancycompletedS
1848-05-14Tdap vaccinecompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
November 1854A bad lingering sore throat and cold after a long walk in heavy rain on the moors, which made her thin and weakD (CLM-0009)

Family History

RelativeConditionAge at deathEvidence
motherDied in 1821 in her 39th year after a long and painful illness, possibly cancerR (CLM-0003, CLM-0004)
sisterEldest sister: tuberculosis after illness at boarding school; died in 1825 aged 1111D (CLM-0005)
sisterSecond sister: tuberculosis after illness at boarding school; died in 1825 aged 1010D (CLM-0005)
brotherDied in 1848 aged 31 of several conditions made worse by heavy drinking, with tuberculosis among them31D (CLM-0006)
sisterTuberculosis; died in 1848 aged 3030D (CLM-0007)
sisterTuberculosis; died in 1849 aged 2929D (CLM-0007)

Health Concerns

ConcernStatusEvidence
Nausea most of the day for a week and vomiting three or four times a day; she can no longer face meals and has lost about a kilogramactiveS
She is glad of the pregnancy but anxious about her age and about her own health, having lost her mother and her sisters youngactiveS
She asks whether she could carry tuberculosis, since it was in her householdactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 11.6 on 1855-03-24; Leukocytes [#/volume] in Blood by Automated count 8.4 on 1855-01-13; Platelets [#/volume] in Blood by Automated count 248 on 1855-01-13; Sodium [Moles/volume] in Serum or Plasma 137 on 1855-02-10; Potassium [Moles/volume] in Serum or Plasma 4 on 1855-02-10; Chloride [Moles/volume] in Serum or Plasma 101 on 1855-02-10; Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 on 1855-02-10; Urea nitrogen [Mass/volume] in Serum or Plasma 9 on 1855-02-10; Creatinine [Mass/volume] in Serum or Plasma 0.55 on 1855-02-10; Glucose [Mass/volume] in Serum or Plasma 82 on 1855-02-10; Ketones [Mass/volume] in Urine by Test strip 80 on 1855-01-29; Fetal Crown Rump length US 70 on 1855-02-24; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 on 1855-01-13; Magnesium [Mass/volume] in Serum or Plasma 1.9 on 1855-02-10; Phosphate [Mass/volume] in Serum or Plasma 3.4 on 1855-02-10; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 on 1855-02-10; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1855-02-10; Thyrotropin [Units/volume] in Serum or Plasma 0.92 on 1855-03-24; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.1 on 1855-03-24; Total score [EPDS] 5 on 1855-03-24; Fetal nuchal translucency measured by US 1.5 on 1855-02-24 [S]

Strengths and supports: Supports: her husband, a close friend from school days with whom she writes often, and the household's long-serving help [S]

Problems

ProblemClinical statusVerificationCodeProvenance
First pregnancy at 38 (elderly primigravida), single live intrauterine pregnancy dated by ultrasound at 7 weeks 1 dayactiveconfirmed O09.519S — Synthetic modern prenatal care anchored to the documented report that she was pregnant when she died; the pregnancy itself is questioned in one source (CLM-0019).
Nausea and vomiting of pregnancy, moderate (PUQE-24 score 10), with early weight loss, under evaluation for hyperemesis gravidarumresolvedconfirmed O21.9S — Synthetic presenting concern at the index visit, superseded by the hyperemesis gravidarum diagnosis at the sick visit; her documented "perpetual nausea" is D and the hyperemesis reading of it is R.
Hyperemesis gravidarum with metabolic disturbance: unable to keep fluids down, 7.4 percent weight loss, dehydration, hypokalemia, hyponatremia, hypochloremic alkalosis, low magnesium, and raised transaminases; PUQE-24 score 14activeconfirmed O21.1S — Synthetic modern diagnosis linked to her documented final illness and the retrospective hyperemesis interpretation; it is not asserted as her historical diagnosis.
Gestational transient thyrotoxicosis: suppressed TSH and mildly raised free T4 with hyperemesis, no goiter, eye signs, or tremor; no treatment neededresolvedconfirmed O99.281S — Synthetic finding that teaches the thyroid tests in hyperemesis; it echoes no documented illness.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1855-01-13Hemoglobin [Mass/volume] in Blood12.8g/dL11-15.5 g/dLNormalS
1855-01-13Leukocytes [#/volume] in Blood by Automated count8.410*3/uL4-13 10*3/uLNormalS
1855-01-13Platelets [#/volume] in Blood by Automated count24810*3/uL150-400 10*3/uLNormalS
1855-01-13Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1855-01-13Potassium [Moles/volume] in Serum or Plasma3.9mmol/L3.5-5.1 mmol/LNormalS
1855-01-13Chloride [Moles/volume] in Serum or Plasma102mmol/L98-107 mmol/LNormalS
1855-01-13Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
1855-01-13Urea nitrogen [Mass/volume] in Serum or Plasma8mg/dL6-20 mg/dLNormalS
1855-01-13Creatinine [Mass/volume] in Serum or Plasma0.52mg/dL0.4-0.9 mg/dLNormalS
1855-01-13Glucose [Mass/volume] in Serum or Plasma76mg/dL70-99 mg/dLNormalS
1855-01-13Ketones [Mass/volume] in Urine by Test strip15mg/dL<=0 mg/dLHighS
1855-01-13Fetal Crown Rump length US11mmConsistent with 7 weeks 1 day by the last menstrual periodNormalS
1855-01-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1855-01-20Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
1855-01-20Potassium [Moles/volume] in Serum or Plasma3.6mmol/L3.5-5.1 mmol/LNormalS
1855-01-20Chloride [Moles/volume] in Serum or Plasma99mmol/L98-107 mmol/LNormalS
1855-01-20Carbon dioxide, total [Moles/volume] in Serum or Plasma26mmol/L22-29 mmol/LNormalS
1855-01-20Urea nitrogen [Mass/volume] in Serum or Plasma11mg/dL6-20 mg/dLNormalS
1855-01-20Creatinine [Mass/volume] in Serum or Plasma0.58mg/dL0.4-0.9 mg/dLNormalS
1855-01-20Glucose [Mass/volume] in Serum or Plasma74mg/dL70-99 mg/dLNormalS
1855-01-20Ketones [Mass/volume] in Urine by Test strip40mg/dL<=0 mg/dLHighS
1855-01-29Hemoglobin [Mass/volume] in Blood14.1g/dL11-15.5 g/dLNormalS
1855-01-29Sodium [Moles/volume] in Serum or Plasma133mmol/L135-145 mmol/LLowS
1855-01-29Potassium [Moles/volume] in Serum or Plasma3.1mmol/L3.5-5.1 mmol/LLowS
1855-01-29Chloride [Moles/volume] in Serum or Plasma94mmol/L98-107 mmol/LLowS
1855-01-29Carbon dioxide, total [Moles/volume] in Serum or Plasma31mmol/L22-29 mmol/LHighS
1855-01-29Urea nitrogen [Mass/volume] in Serum or Plasma21mg/dL6-20 mg/dLHighS
1855-01-29Creatinine [Mass/volume] in Serum or Plasma0.71mg/dL0.4-0.9 mg/dLNormalS
1855-01-29Glucose [Mass/volume] in Serum or Plasma68mg/dL70-99 mg/dLLowS
1855-01-29Magnesium [Mass/volume] in Serum or Plasma1.6mg/dL1.7-2.2 mg/dLLowS
1855-01-29Phosphate [Mass/volume] in Serum or Plasma2.6mg/dL2.5-4.5 mg/dLNormalS
1855-01-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma66U/L7-35 U/LHighS
1855-01-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma49U/L10-35 U/LHighS
1855-01-29Thyrotropin [Units/volume] in Serum or Plasma0.03m[IU]/L0.1-2.5 mIU/LLowS
1855-01-29Thyroxine (T4) free [Mass/volume] in Serum or Plasma2.1ng/dL0.8-1.8 ng/dLHighS
1855-01-29Ketones [Mass/volume] in Urine by Test strip80mg/dL<=0 mg/dLHighS
1855-02-10Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1855-02-10Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
1855-02-10Chloride [Moles/volume] in Serum or Plasma101mmol/L98-107 mmol/LNormalS
1855-02-10Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
1855-02-10Urea nitrogen [Mass/volume] in Serum or Plasma9mg/dL6-20 mg/dLNormalS
1855-02-10Creatinine [Mass/volume] in Serum or Plasma0.55mg/dL0.4-0.9 mg/dLNormalS
1855-02-10Glucose [Mass/volume] in Serum or Plasma82mg/dL70-99 mg/dLNormalS
1855-02-10Magnesium [Mass/volume] in Serum or Plasma1.9mg/dL1.7-2.2 mg/dLNormalS
1855-02-10Phosphate [Mass/volume] in Serum or Plasma3.4mg/dL2.5-4.5 mg/dLNormalS
1855-02-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-35 U/LNormalS
1855-02-10Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L10-35 U/LNormalS
1855-02-10Total score [EPDS]9{score}S
1855-02-24Fetal Crown Rump length US70mmConsistent with 13 weeks 1 day by the dating scanNormalS
1855-02-24Fetal nuchal translucency measured by US1.5mm<=3.5 mmNormalS
1855-03-24Hemoglobin [Mass/volume] in Blood11.6g/dL11-15.5 g/dLNormalS
1855-03-24Thyrotropin [Units/volume] in Serum or Plasma0.92m[IU]/L0.2-3 mIU/LNormalS
1855-03-24Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
1855-03-24Total score [EPDS]5{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1855-01-13Body height152cmS
1855-01-13Body weight45.1kgS
1855-01-13Body mass index (BMI) [Ratio]19.5kg/m2S
1855-01-13Systolic blood pressure104mm[Hg]S
1855-01-13Diastolic blood pressure66mm[Hg]S
1855-01-13Heart rate84/minS
1855-01-13Respiratory rate14/minS
1855-01-13Body temperature36.7CelS
1855-01-13Oxygen saturation in Arterial blood by Pulse oximetry99%S
1855-01-20Body height152cmS
1855-01-20Body weight44kgS
1855-01-20Body mass index (BMI) [Ratio]19kg/m2S
1855-01-20Systolic blood pressure102mm[Hg]S
1855-01-20Diastolic blood pressure64mm[Hg]S
1855-01-20Heart rate92/minS
1855-01-20Respiratory rate14/minS
1855-01-20Body temperature36.8CelS
1855-01-20Oxygen saturation in Arterial blood by Pulse oximetry99%S
1855-01-29Body height152cmS
1855-01-29Body weight42.6kgS
1855-01-29Body mass index (BMI) [Ratio]18.4kg/m2S
1855-01-29Systolic blood pressure96mm[Hg]S
1855-01-29Diastolic blood pressure60mm[Hg]S
1855-01-29Heart rate108/minS
1855-01-29Respiratory rate16/minS
1855-01-29Body temperature36.9CelS
1855-01-29Oxygen saturation in Arterial blood by Pulse oximetry99%S
1855-02-10Body height152cmS
1855-02-10Body weight43.6kgS
1855-02-10Body mass index (BMI) [Ratio]18.9kg/m2S
1855-02-10Systolic blood pressure104mm[Hg]S
1855-02-10Diastolic blood pressure64mm[Hg]S
1855-02-10Heart rate86/minS
1855-02-10Respiratory rate14/minS
1855-02-10Body temperature36.7CelS
1855-02-10Oxygen saturation in Arterial blood by Pulse oximetry99%S
1855-02-24Body height152cmS
1855-02-24Body weight44.4kgS
1855-02-24Body mass index (BMI) [Ratio]19.2kg/m2S
1855-02-24Systolic blood pressure106mm[Hg]S
1855-02-24Diastolic blood pressure66mm[Hg]S
1855-02-24Heart rate82/minS
1855-02-24Respiratory rate14/minS
1855-02-24Body temperature36.6CelS
1855-02-24Oxygen saturation in Arterial blood by Pulse oximetry99%S
1855-03-24Body height152cmS
1855-03-24Body weight46.2kgS
1855-03-24Body mass index (BMI) [Ratio]20kg/m2S
1855-03-24Systolic blood pressure108mm[Hg]S
1855-03-24Diastolic blood pressure68mm[Hg]S
1855-03-24Heart rate80/minS
1855-03-24Respiratory rate14/minS
1855-03-24Body temperature36.7CelS
1855-03-24Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
1855-01-13First prenatal visit at 7 weeks with nausea and vomiting for a week and early weight loss: dating ultrasound, prenatal tests, and a plan for the nauseafinishedS
1855-01-20One-week review of nausea and vomiting, intake results, and maternal-fetal medicine consultationfinishedS
1855-02-10Prenatal visit at 11 weeks: nausea and vomiting review and cell-free DNA screeningfinishedS
1855-02-24Prenatal visit at 13 weeks with the nuchal translucency scan and the low-dose aspirin decisionfinishedS
1855-03-24Prenatal visit at 17 weeks: nausea and vomiting review and thyroid recheckfinishedS
1855-01-29Same-day sick visit for vomiting with dehydration at 9 weeks, with direct admissionfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
First prenatal visit: dating ultrasound; blood count, blood group and antibody screen, rubella immunity, hepatitis B surface antigen, HIV, syphilis, and hepatitis C tests; urine culture; metabolic panel and urinalysis because of vomiting; influenza vaccine; folic acid 0.4 mg daily in place of the iron-containing prenatal vitamin while nausea lastscompletedGL-USPSTF-AB, GL-CDC-PREGVAXS
Nausea and vomiting, step by step: small frequent dry meals, fluids between meals, ginger if she wishes, and avoiding smells that trigger nausea; doxylamine-pyridoxine from today, raised to four tablets a day if needed; then a second drug (metoclopramide, promethazine, or ondansetron after counseling); PUQE-24 score, weight, pulse, blood pressure, and electrolytes at each visit; same-day review if she cannot keep fluids down for 24 hours or loses more than 5 percent of her pre-pregnancy weightcompletedGL-ACOG-NVP-2018, GL-RCOG-HG-2024S
Maternal-fetal medicine consultation for a first pregnancy at 38 with moderate nausea and vomiting and early weight loss: escalation thresholds, aneuploidy screening and diagnostic options, preeclampsia prevention, tuberculosis risk, and the plan for the rest of the pregnancycompletedGL-ACOG-NVP-2018, GL-RCOG-HG-2024, GL-ACOG-ANEU-2020, GL-USPSTF-ASA-2021S
Aneuploidy screening offered to all, with diagnostic testing available: cell-free DNA from 10 weeks, a nuchal translucency scan at 11 to 14 weeks, or chorionic villus sampling or amniocentesis; a detailed anatomy scan at 18 to 22 weekscompletedGL-ACOG-ANEU-2020S
Tuberculosis screening with an interferon-gamma release assay because of tuberculosis deaths in her household; a shielded chest radiograph and treatment decisions only if it is positivecompletedGL-USPSTF-LTBI-2023S
Mental health: PHQ-9 at intake and the EPDS in each trimester and after any admission, with support for the strain of severe vomiting and for anxiety rooted in family losscompletedGL-ACOG-MH-2023, GL-USPSTF-PND-2019S
Preeclampsia prevention: low-dose aspirin 81 mg at bedtime from 12 to 16 weeks until delivery if she has one high-risk or more than one moderate-risk factor (she has two: first pregnancy and age 35 or older); blood pressure at every visitcompletedGL-USPSTF-ASA-2021S
Admission for hyperemesis gravidarum: 0.9% saline with potassium chloride guided by daily electrolytes; thiamine 100 mg intravenously before any dextrose, then orally; magnesium replacement; ondansetron after counseling and an electrocardiogram; stop metoclopramide; refeeding precautions with phosphate and magnesium checks as eating resumes; weight-adjusted enoxaparin while admitted; discharge when she keeps fluids and food downcompletedGL-ACOG-NVP-2018, GL-RCOG-HG-2024, GL-RCOG-VTE-2015S
Thyroid: suppressed TSH with a mildly raised free T4 during hyperemesis is gestational transient thyrotoxicosis; no antithyroid drug; repeat TSH and free T4 at 16 to 18 weeks, and test for TSH-receptor antibodies only if it persists or signs of Graves disease appearcompletedGL-ATA-PREG-2017, GL-ACOG-NVP-2018S
Monitoring while nausea and vomiting last: PUQE-24, weight, pulse, and blood pressure at every visit; electrolytes until stable on oral intake; liver tests if abnormal; mood each trimester; antiemetic side effects (drowsiness, restlessness or abnormal movements, constipation, palpitations)completedGL-ACOG-NVP-2018, GL-RCOG-HG-2024S

Goals

GoalTargetStatusOutcomeProvenance
Nausea and vomiting mild (PUQE-24 score 6 or less) and weight back to her pre-pregnancy 46.0 kg by about 17 weeks1855-03-24completedPUQE-24 score 4 and weight 46.2 kg at 17 weeks 1 dayS
Hydration and electrolytes normal within two weeks of any admission1855-02-10completedSodium, potassium, chloride, bicarbonate, magnesium, phosphate, and transaminases all normal nine days after dischargeS
An informed choice about aneuploidy screening and diagnostic testing by 13 weeks1855-02-24completedChose cell-free DNA screening (low risk) and the nuchal translucency scan (1.5 mm); declined diagnostic testingS
Low-dose aspirin started between 12 and 16 weeks if indicated1855-02-24completedStarted at 13 weeks 1 day for two moderate risk factorsS
Tuberculosis screening completed and explained by the second visit1855-01-20completedInterferon-gamma release assay negative; no latent infection; no chest radiograph neededS
Mood screened in each trimester, with support offered1855-03-24completedPHQ-9 5 at intake, EPDS 9 after the admission and 5 at 17 weeks; item 10 scored 0 each timeS

Functional Status

Mental Status